ArticleOncoimmunology2022
Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.
Antonino Di Lorenzo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
23 papers cite it
this paperpooled itcites it